| Bioactivity | Etalocib (LY293111), an orally active leukotriene B4 receptor antagonist, inhibits the binding of [3H]LTB4, with a Ki of 25 nM. Etalocib (LY293111) prevents LTB4-induced calcium mobilization with an lC50 of 20 nM. Etalocib (LY293111) induces apoptosis[1][2][3]. | ||||||||||||
| Invitro | Etalocib (LY293111) elicits a concentration-dependent inhibition of LTB4 induced CD11b up-regulation[1].Etalocib (LY293111) is an extremely potent and selective antagonist of human neutrophil function in vitro[2].Etalocib (LY293111, 250 and 500 nM, 24-72 h) induces apoptosis and inhibits proliferation in human pancreatic cancer cells[3]. Cell Proliferation Assay[3] Cell Line: | ||||||||||||
| Name | Etalocib | ||||||||||||
| CAS | 161172-51-6 | ||||||||||||
| Formula | C33H33FO6 | ||||||||||||
| Molar Mass | 544.61 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|